Press release - 12 August 2003

CapMan strengthens its Life Science operations in Finland – Yrjö Wichmann appointed as Investment Director

Mr. Yrjö Wichmann (44) has been appointed as Investment Director in CapMan’s Nordic Life Science Business Unit as of 1 October 2003. He has over ten years’ experience from the Finnish life science market. Wichmann transfers to CapMan from FibroGen Europe Corp. where he has acted as CFO. Previously he worked in D.Carnegie AB’s Finland branch as a director in corporate finance, responsible for life science and healthcare sectors.

“On their way to success, emerging Finnish life science companies need alternative funding sources and partners that can also provide and help them with contacts, management resources, business skills and operational advice. I believe that CapMan, as a leading private equity investor in the Nordic area, is able to support emerging companies in a number of ways starting from wide contact network and resource pool to solid operational and management systems. The expansion of CapMan’s life science team to Finland is thus an exciting opportunity for the Finnish life science industry in general and me personally”, says Yrjö Wichmann.

“Yrjö Wichmann has a solid executive experience and a broad network within life science and we are very pleased that he is joining the CapMan life science team. Yrjö will play a key-role in our expansion in Finland,” says Jan Lundahl, who is the Head of CapMan´s Life Science Business Unit. ”During the fall of 2003 we will continue our unit’s expansion also to Denmark,” Lundahl continues.


For more information, please contact:
Jan Lundahl, Head of CapMan Life Science Business Unit, +46 8 545 854 70, mobile +46 708 56 19 53
Jerome Bouix, Director of Investor Relations and Communications, +358 40 820 8541

CapMan Group
CapMan is one of the leading private equity investors in the Nordic countries and specialises in mid-sized buyouts in various industry sectors, technology investments in the IT and telecommunications sectors and investments in life science companies. CapMan team comprises around 80 people in Helsinki, Stockholm and Copenhagen. CapMan manages/advises funds with approximately EUR 1.653 billion in total capital, of which app. EUR 527 million is managed by the affiliated company Access Capital Partners, which invests in European private equity funds. To date, the funds managed by CapMan have invested in 133 companies in the Nordic countries and exited from 54 companies. The latest investments are made in Finnish Distocraft Oy, in Swedish Metallfabriken Ljunghäll AB and in Danish Eco-Dan A/S. CapMan Plc is listed on the Main List of the Helsinki Stock Exchange.

   

‹ Takaisin edelliselle sivulle